iCAD (NASDAQ:ICAD) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

iCAD (NASDAQ:ICAD) posted its quarterly earnings results on Wednesday. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02, Zacks reports. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The business had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million.

iCAD Trading Up 6.5 %

Shares of iCAD stock opened at $2.47 on Thursday. The company has a market capitalization of $65.55 million, a PE ratio of -19.00 and a beta of 1.95. iCAD has a 12 month low of $1.18 and a 12 month high of $3.78. The stock’s fifty day simple moving average is $2.64 and its 200 day simple moving average is $2.05.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered iCAD from a “hold” rating to a “sell” rating in a research report on Tuesday.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.